• A
  • |
  • A
  • Text size

Advocacy with the Administration

The AMA continues to advocate for changes to decrease the regulatory burden on physicians. Learn more about the AMA’s instrumental role in securing regulatory improvements and significant legislative victories at the federal and state levels.

2016 Physician Payment Schedule
2015 Physician Payment Schedule
2014 Physician Payment Schedule
Administrative Simplification
Antitrust Reform

The AMA is urging the Federal Trade Commission (FTC) and the Department of Justice (DOJ) to shift the focus on current physician antitrust policy to remove obstacles that prevent physicians from forming clinically integrated networks that can jointly negotiate with health plans for the purposes of participating in quality improvement programs and HIT initiatives. The AMA is also urging the DOJ to increase its oversight of health insurer consolidation.

Comments to FTC re: Examining Health Care Competition workshop, April 30, 2015.

Comments to FTC re: Examining Health Care Competition workshop, April 30, 2014

Comments to DOJ re: U.S. v Humana Inc and Arcadian Management Services Inc: Proposed final Judgment, June 4, 2012

AMA Comments to proposed Consent Judgment in U.S. v. Blue Cross and Blue Shield of Montana, Inc,, et al, January 13, 2012

AMA statement to the Committee on Ways and Means, U.S. House of Representatives, on health industry consolidation, September 9, 2011

AMA White Paper proposes an effective Antitrust reform remedy

AMA letter to Assistant Attorney General Christine Varney regarding competition in health insurance and other antitrust matters, July 8, 2009

Statement to the Committee on Small Business, U.S. House of Representatives, on Small business Competition Policy: Are Markets Open for Entrepreneurs? September 25, 2008

Statement to the U.S. Senate Judiciary Committee, Subcommittee on Antitrust, Competition Policy, and Consumer Rights given by Henry S. Allen, Jr. Esq. on Consolidation in the Pennsylvania Health Insurance Industry: The Right Prescription? July 31, 2008

Learn More

Comparative Effectiveness Research

The purpose of CER is to enhance physician clinical decision-making and foster the delivery of patient-centered care. Most current research on medical treatments compares the benefits of a specific treatment to no treatment, but little information is available to physicians to help them determine if new treatments outperform existing options.

Physicians today have access to a wide array of medical information. However, there remains far too little rigorous evidence available about which treatments work best for which patients. The AMA strongly supports increased federal funding of comparative effectiveness research (CER). Though there are a broad array of areas where CER would bring benefits, the health care community must strategically target support for CER where it will significantly improve health care value by enhancing physician clinical judgment, foster the delivery of patient-centered care, and produce substantial benefit to the health care system as a whole.

AMA CER principles

November 22, 2011, letter responding to Agency Information Collection Request regarding the Multi-Payor Claims Database

DEA Issues

The Drug Enforcement Administration (DEA) registration number system was implemented as a way to successfully track controlled substances from the time they are manufactured until the time they are dispensed to the patient. The AMA strongly opposes the use of the DEA number for purposes other than its original intent.

Drug Shortages
AMA provided comments to the FDA on its draft guidance for Mixing, Diluting, and Repackaging Biological Products on May 20, 2015. Whilst expressing support for the FDA's goals of ensuring the quality and safety of the nation's compounded and repackaged drug supply, AMA also urged that FDA also consider the access needs of physicians and patients.

In a December 27, 2013 letter to the FDA, the AMA provided comments on FDA’s proposed rule that would require manufacturers to notify the agency of a permanent discontinuance or manufacturing interruption of a product that is likely to lead to a meaningful disruption in supply.

The AMA provided recommendations to the Food and Drug Administration's (FDA) Drug Shortages Task Force on its Strategic Plan in a March 14, 2013 letter. In its letter, the AMA highlighted physician concern and frustration with ongoing shortages, particularly of sterile injectables. In addition, AMA indicated its support of the concept of developing a qualified manufacturing partner program; and strongly supported targeted notification to physician medical specialty organizations.

e-Prescribing for Controlled Substances
On March 31, 2010 the DEA published an interim final rule (IFR) permitting physicians to prescribe controlled substances electronically as of June 1, 2010. The IFR specifies the rules that physicians and other health care providers must follow in order to e-prescribe controlled substances. The AMA together with several medical specialty societies commented on the DEA's proposed rule in 2008 and the IFR in 2010. While the DEA made a number of positive changes in the final rule, there are still a number of e-prescribing requirements specific to controlled substances that physicians must comply with. E-prescribing for controlled substances remains optional for physicians. For those physicians who would like to prescribe controlled substances electronically, the DEA requires what is known as a "two-factor authentication." Authentication is information (e.g., PINs, passwords, biometrics) that is used to verify a person’s identity for security purposes. According to the IFR, when e-prescribing controlled substances, physicians must use two out of three factors: something you know (e.g., passwords), something you have (e.g., hard token stored separately from the computer being accessed like a USB device or smart card), or something you are (e.g., biometrics such as a fingerprint or iris scan). While the effective date is June 1, before physicians can prescribe controlled substances electronically, vendors must make their e-prescribing applications compliant with the IFR requirements and undergo a third-party audit before changes to physician's software can be made. In addition, physicians must undergo a verification process (either in person or remotely) with a federally approved entity in order to receive authorization to e-prescribe controlled substances. Also, please check with your vendor to ensure that their system is compliant with the DEA requirements and check if your State law allows you to e-prescribe controlled substances.

August 2015 letter to DEA regarding e-Prescribing for Controlled Substances

Fact Sheet on e-Prescribing for Controlled Substances

DEA Interim Final Rule on e-Prescribing for controlled substances

May 2010 comment letter to DEA on Interim Final Rule on e-Prescribing

September 2008 comment letter to DEA on Proposed Rule on e-Prescribing

Prescribing in Long-Term Care Settings
Tip Sheet for Practicing Clinicians: Prescribing Controlled Substances in Long-Term Care

Letter to DEA in regarding prescribing controlled drugs at long term care facilities

DEA Fees
Congress requires the DEA's Office of Drug Diversion Control to be self-funded. Therefore, DEA registration fees support this office. However, DEA fees are disproportionately high for physician prescribers compared to others like manufacturers and distributors, something the AMA has vigorously opposed. The three-year cost for a physician DEA registration is $551 which also represents a steep increase over prior practitioners registration feeds. Furthermore, the DEA requires physicians to obtain a DEA number for each state where they prescribe adding potentially more costs for physicians.

June 6, 2007 Letter to the DEA Opposing High Fees

Other DEA Issues
Letter from the DEA clarifying that physicians may orally prescribe Schedule II controlled substances in emergency situations

Emergency Medical Treatment and Labor Act (EMTALA)

On December 23, 2010, CMS published an Advanced Notice of Proposed Rulemaking on the Emergency Medical Treatment and Labor Act (EMTALA). That ANPRM indicated that CMS was reconsidering its current policy which provides that: 1) a hospital’s EMTALA obligation ends upon the admission of a patient as an inpatient, and 2) EMTALA does not apply to the transfer of an inpatient to a hospital with specialized capabilities.

The AMA submitted comments in response to the ANPRM that strongly objected to the extension of EMTALA to the inpatient setting or to the transfer of an inpatient to a hospital with specialized capabilities. The AMA reasoned that physicians are already bound by a host of legal and ethical obligations to provide necessary patient care, and take those obligations seriously. Further, the AMA asserted that EMTALA obligations often result in over-utilization of physician resources, uncompensated care, and administrative hurdles.

On February 2, 2011, CMS published a Request for Comment in which CMS states that it is maintaining its current policy that EMTALA does not extend to inpatients or to the transfer of inpatients to hospitals with specialized capabilities. CMS says that it will continue to monitor whether it may be appropriate in the future to reconsider the inapplicability of EMTALA to the transfer of inpatients to hospitals with specialized capabilities, and invites comment on that issue. The AMA commented in support of CMS' decision not to extend EMTALA.

FDA Issues

AMA urges that FDA modify risk reduction plans
The AMA wrote Food and Drug Administration (FDA) Commissioner Margaret Hamburg, MD, to express concern about the manner in which FDA has been implementing the Risk Evaluation and Mitigation Strategies (REMS) provisions of a 2007 law and recommend improvements. The AMA believes that REMS should support physician decision-making and help promote safe prescribing without erecting barriers to delivery of appropriate care. The FDA has not required manufacturers to obtain input from practicing physicians on “elements to assure safe use” when such elements are included in REMS; however, nor has it outlined methods to assess the impact of REMS on patient access to needed drugs. In its letter, the AMA recommended that the FDA: require this type of consultation with specialty societies and practicing physicians; ensure that manufacturers evaluate the impact of REMS on patient access and clinical practice; provide for review of proposed REMS by the FDA Advisory Committees; and reduce the administrative burdens associated with REMS. In response to the concerns expressed by AMA and other stakeholders, the FDA convened a public meeting on July 27-28, 2010, and reopened the comment period on its draft guidance on REMS. Dr. Sandra Fryhofer of the AMA Council on Science and Public Health represented the AMA at the public meeting.

FDA Plans for Opioids
Last year the FDA announced an initiative to work with manufacturers of extended-release and high-potency opioids to develop a Risk Evaluation and Mitigation Strategy or REMS. In meetings, testimony at public hearings, and comment letters, AMA has urged the agency to: ensure that the REMS does nothing to impair patient access to needed pain medications; seek a REMS focused primarily on educating physicians and patients; provide positive incentives rather than penalties; allow substantial opportunities for physician involvement in designing the educational programs; avoid restricted distribution; and work to prevent unintended consequences such as an increase in use of immediate-release opioids that are not included in the REMS or undertreatment of pain.

AMA comments to FDA regarding its revised guidance on blood donations from men who have sex with men, July 13, 2015

AMA letter to FDA regarding current blood donor deferral policy for MSM, Nov, 18, 2014

Letter to FDA supporting its conclusion that partially hydrogenated oils are no longer “generally recognized as safe,” March 7, 2014

Letter to FDA on draft guidance on risk evaluation and mitigation strategies, Aug. 30, 2010

AMA letter to FDA on opioid REMS proposal, July 8, 2010

Joint comment letter to FDA on opioids REMS development from AMA and 15 specialties, June 30, 2009

AMA comment letter on Direct-to-Consumer Advertising, January 29, 2009

Fraud and Abuse

The AMA is working to ensure that fraud and abuse laws and enforcement do not unduly burden honest physicians.

2015 Annual Anti-Kickback Statute comments to HHS OIG, March 2, 2015

Sign-on letter to CMS regarding extension of prior authorization and prepayment programs, January 29, 2015

AMA comments to HHS OIG - Medicare and State Health Care Programs: Fraud and Abuse; Revisions to Safe Harbors under the Anti-Kickback Statute, and CMP Rules Regarding Beneficiary Inducements and Gainsharing, December 1, 2014

AMA comments to CMS regarding the proposed rule, Prior Authorization Process for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Items, July 28, 2014

AMA letter to CMS, ONC, and OIG on EHR Program Integrity Guidance, June 5, 2014

AMA comments in response to CMS’ PRA data collection notice seeking to audit PQRS and e-Rx Programs, May 16, 2014

2014 Annual Anti-Kickback Statute comments to HHS OIG, February 25, 2014

Electronic Health Records (EHR) Waiver letter to OMB, December 18, 2013

August 23, 2013 letter to CMS regarding Incarcerated Medicare Beneficiaries

July 19, 2013 comment letter to CMS urging reevaluation of its program integrity proposals for qualified health plan issuers

AMA comments regarding the Medicare Incentive Reward Program and Provider Enrollment, June 28, 2013

June 25, 2013 comment letter to CMS on Medicare 2014 Inpatient Prospective Payment Systems (IPPS)

AMA comments regarding OIG and CMS proposal to extend the sunset for the Anti-Kickback Statute/Stark EHR safe harbor, June 10, 2013

2013 Annual Anti-Kickback Statute comments to HHS OIG, February 26, 2013

Whitepaper: "Medicare and Medicaid program integrity: Recommendations for greater value and efficiency" (November 2012)

AMA letter to HHS re: Public-Private Partnership to Prevent Health Care Fraud, October 1, 2012

AMA comments to HHS OIG regarding recommended updates to the Provider Self-Disclosure Protocol, August 17, 2012

AMA letter to HRSA - Healthcare Integrity and Protection Data Bank (HIPDB) and National Practitioner Data Bank (NPDB) elimination of duplication, April 16, 2012

Sign-on letter to CMS - Reporting and Returning Overpayments, April 16, 2012

2012 Annual Anti-Kickback Statute Comments to HHS OIG, February 27, 2012

AMA letter to CMS on prepayment review OMB clearance request, December 14, 2011

CMS Identity Theft Victim Program, October 2011

AMA letter to CMS on predictive modeling, August 8, 2011

AMA letter to CMS on screening requirements, March 30, 2011

AMA letter to CMS on screening requirements, November 16, 2010

AMA letter to HHS on physician identity theft, November 18, 2010

Health IT / EHR Incentives

Health information technology (Health IT) encompasses a wide range of products and systems, including software, hardware and infrastructure, that are used to support the collection, storage and exchange of patient data throughout the clinical practice of medicine. Health Information Technology (Health IT) is a term that encompasses a huge range of products and systems. There are many public and private initiatives currently promoting and developing effective Health IT.

Read more

HIPAA / 5010 / ICD-10 / Privacy

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) prompted new Federal regulations which require physicians to ensure they are protecting the privacy and security of patients' medical information and using a standard format when submitting electronic transactions, such as submitting claims to payers.

Payers who conduct business electronically need to be aware of two significant changes concerning standard transactions and code sets. On January 16, 2009, the Department of Health and Human Services (HHS) announced two new compliance deadlines.

Read more

Home Health and Hospice Face-to-Face Encounter Requirements

Effective April 1, 2011, CMS expects home health agencies and hospices have fully established internal processes to comply with the face-to-face encounter requirements mandated by the Affordable Care Act (ACA) for purposes of certification of a patient’s eligibility for Medicare home health services and of recertification for Medicare hospice services. Section 6407 of ACA established a face-to-face encounter requirement for certification of eligibility for Medicare home health services, by requiring the certifying physician to document that he or she, or a non-physician practitioner working with the physician, has seen the patient. The encounter must occur within the 90 days prior to the start of care, or within the 30 days after the start of care. Documentation of such an encounter must be present on certifications for patients with starts of care on or after January 1, 2011. CMS had originally proposed a much short time frame for when the encounter had to occur, however, due to AMA advocacy, CMS extended the timeframe. Similarly, section 3131(b) of ACA requires a hospice physician or nurse practitioner to have a face-to-face encounter with a hospice patient prior to the patient’s 180th-day recertification, and each subsequent recertification. The encounter must occur no more than 30 calendar days prior to the start of the hospice patient’s third benefit period. The provision applies to recertifications on and after January 1, 2011.

AMA Correspondence on Face-to-Face Encounters
December 23, 2010 Letter to CMS on the Face-to-Face Encounter Requirements

Additional Resources
AMA Guide on Medical Management of Home Care Patient
CMS Home Health Agency Center
CMS Hospice Center
CMS MLN Matters article (SE0138) on general requirements
CMS MLN Matters article (SE0415) on documentation requirements including examples of incorrect documentation and information on improper payments

Hospital Observation Status

The AMA is concerned about the negative impacts on patients and physicians resulting from retroactive changes to hospital admission status and increased placement in observation care. To alleviate these problems, the AMA is advocating for rescission of the three-day inpatient stay requirement for patient coverage of skilled nursing facility (SNF) care, increased transparency of commercial black-box edit software and physician decision-making regarding admission status; and for physicians to be held harmless from audits related to admission status.

AMA comment letter on Hospital Inpatient Prospective Payment Systems, June 27, 2014

AMA/AHA letter to CMS supporting delayed enforcement of the two-midnight policy, November 8, 2013

June 25, 2013 comment letter to CMS on Medicare 2014 Inpatient Prospective Payment Systems (IPPS)

Patient Admission Status/Part B Inpatient Billing: AMA comments to CMS, May 16, 2013

Observation Care/Hospital Outpatient Rule: AMA comments to CMS, August 31, 2012


The Affordable Care Act (ACA) significantly expands those covered by Medicaid. As a result of the new law and the 2012 decision by the US Supreme Court on the constitutionality of the ACA, states can decide whether to expand their Medicaid programs to cover all non-Medicare eligible individuals under 65 years of age with incomes up to 133% of the federal poverty level (FPL) based on modified gross income. Through this change, Medicaid is expected to cover an additional 16 million people beginning in 2014.

January 4, 2016 comment letter to CMS concerning Medicaid access

February 21, 2013 comment letter to CMS concerning Medicaid

July 19, 2012 letter to CMS re: State Demonstrations to Integrate Care for Dual Eligibles

July 5, 2011 sign-on letter on the proposed Rule, Methods for Assuring Access Covered Medicaid Services

Medical Liability Reform

As a result of AMA Advocacy, in September, 2009, President Obama directed the HHS Agency for Healthcare Research and Quality (AHRQ) to implement a $25 million state-based demonstration project on Medical Liability Reform and Patient Safety. The demonstrations will help states and health care systems to test models that meet four goals:

  • Put patient safety first and work to reduce preventable injuries;
  • Foster better communication between doctors and patients;
  • Ensure that patients are compensated in a fair and timely manner for medical injuries, while also reducing the incidence of frivolous lawsuits; and
  • Reduce liability premiums

Learn more about the need for medical liability reform

The first grant program is funding for one-year planning grants to create plans for development, implementation and evaluation of approaches that focus on medical liability reform and patient safety. These are one-year grants for up to $300,000 each. The second program is funding for three-year demonstration projects to allow States and health systems who are ready to go to develop, implement, and evaluate medical liability models that focus on patient safety and reform the medical liability system. These are three-year grants for up to $3 million dollars each.

State medical associations are not eligible to apply for grants on their own directly. Those eligible to apply are states and "health systems". Medical associations can be a "component" of a health system if in coalition with them. Criteria listed to qualify address both patient safety and MLR reform and are drafted broadly. The language does not limit the type of reforms that may be considered—applicants will have wide discretion and flexibility in designing their patient safety and medical liability innovations that meet specified criteria (i.e., health courts, early offer programs, and administrative-type programs may all be considered if they meet the patient safety and medical liability objectives.)

The grant application period opens December 27th and will close January 27th. Funding decisions will be made within four months.

Both grant announcements are available at the following links:

An Advisory Subcommittee has been established to advise AHRQ on the review criteria in the announcement or clarify additional issues for applicants. William Hazel, MD, an AMA Trustee and an orthopedic surgeon, serves on the Subcommittee.

Medicare Advantage and Part D

AMA comments to CMS on 2017 Advance Notice for MA and Part C & D – 2017 Draft Call Letter, March 4, 2016

Comments to CMS regarding 2016 Advance Notice for MA and Part C and D – 2016 Call Letter, March 6, 2015

AMA comments to CMS on draft revisions to Medicare Rx Drug Benefit Manual – Chapter 6, February 20, 2015

Sign-on letter to CMS requesting increased patient protections in MA plan offerings in 2016 Call Letter, February 12, 2015

Letter to CMS regarding Medicare Part D coverage of drugs for patients in hospice, June 23, 2014

CMS memo clarifying the 2014 exception to patient consent for automatic delivery of prescriptions, March 21, 2014

Comments to CMS re: Medicare Program 2015 Contract Year – Part D Medicare Advantage Proposed Rule

Advance Notice of Methodological Changes for Calendar Year 2015 for Medicare Advantage Capitation Rates, Part C and Part D Payment Policies and 2015 Call Letter

Medicare Advantage 2014 Open Enrollment – Transparency and Patients’ Rights sign-on letter

CMS clarification of controlled substances prescribing

CMS guidance to Medicare Advantage plans on implementation of sequester

AMA comment letter to CMS on Methodological Changes for Calendar Year (CY) 2014 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies, and 2014 Call Letter

AMA comment letter to CMS on Advance Notice of Methodological Changes for Calendar Year (CY) 2013 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2013 Call Letter

AMA letter to CMS on Medical Advantage Risk Adjustment Audits

CMS memo to Part D plans on early refills for glaucoma patients

AMA comment letter to CMS on Advance Notice of Changes for CY 2011 Medicare Advantage Capitation Rates, Part C and Part D Payment Policies and 2011 Call Letter

Sign-on letter to CMS opposing fraud training requirements for physicians who contract with MA plans.

Memo from CMS Program Integrity Group to Medicare Advantage plans clarifying fraud and compliance training requirements.

AMA comment letter on the Administration's Draft 2010 Call Letter for Medicare Advantage and Part D Plans

Medicare Physician Payment Reform

Following years of advocacy by the nation's physicians standing up for their patients and their practices, Congress repealed the sustainable growth rate (SGR) formula. H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was signed into law on April 16, 2015.

Read More

Medicare Contracting Reform

As a result of a provision in the Medicare Modernization Act of 2003 (MMA), the Centers for Medicare and Medicaid Services (CMS) has been charged with significantly altering the way they award contracts to carriers and fiscal intermediaries.  Understand how this will impact your process and what you need to know about this transition.

Read more

Medicare Enrollment

The Medicare enrollment process is a critical area of the program as it serves as the gateway into the program. Before physicians can bill Medicare they must submit an enrollment application to their Medicare contractor and have it successfully processed. Learn about the latest changes to the process and how to get your application processed successfully.

Read More

Patient Safety

In 2005 the AMA lead the passage of the Patient Safety and Quality Improvement Act (Public Law 109-41 109th Congress). The AMA will continue to lead physicians' efforts to measurably improve patient safety by working to ensure the law's implementation and to advance other measures, including voluntary reporting systems with strong confidentiality protections.

On November 21, 2008, HHS issued the final rule that establishes the authorities, processes, and requirements for implementing the Patient Safety and Quality Improvement Act of 2005 (the Patient Safety Act). The final rule captures the intent of the Patient Safety Act; to create a voluntary reporting program through which health care providers can share information relating to patient safety events with patient safety organizations (PSOs) on a privileged and confidential basis in order to improve patient safety and the quality of care. The final rule reiterates that this voluntary program is not federally funded but sets forth the framework by which health care providers may voluntarily report information to PSOs, on a privileged and confidential basis, for the collection and analysis of patient safety events. The final rule indicates that the Agency for Healthcare Research and Quality (AHRQ) will implement and oversee the process for certification and listing of PSOs and that the Office of Civil Rights (OCR) will investigate and enforce compliance with the confidentiality requirements.

April 11, 2008, AMA comments submitted to the Agency for Healthcare Research and Quality (AHRQ) on the proposed rule for implementing the Patient Safety law that establishes a federal framework for physicians, hospitals, and other health care professionals and entities to voluntarily report patient safety work product to patient safety organizations (PSOs) on a privileged and confidential basis. Read the letter

Learn More

Patient Centered Outcomes Research Institute (PCORI)

The U.S. Government Accountability Office (GAO) on September 23 announced the appointment of 19 members to the Board of Governors of the new Patient-Centered Outcomes Research Institute (PCORI). Established by the Affordable Care Act (ACA), the PCORI is being set up as a nonprofit organization to fund research projects on the comparative effectiveness of various patient diagnostic, treatment and disease prevention methods. To read more about PCORI, please visit www.pcori.org.

AMA comments on PCORI draft Methodology Report, September 14, 2012

AMA comments on PCORI draft National Priorities and Research Agenda, March 14, 2012

On September 1, 2011 the AMA along with 26 medical specialty organizations responded to PCORI's call for comment on its proposed working definition of "patient centered outcomes research." The letter also includes 2011-2012 Comparative Effectiveness Research priority recommendations.

Physician Financial Transparency Reports (Sunshine Act)

The Physician Payments Sunshine Act, which was part of the Affordable Care Act (ACA), requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal health care programs to report certain payments and items of value given to physicians and teaching hospitals.

Read More

Physician Signature of Lab Requisitions

On November 29, 2010 CMS finalized a requirement in the 2011 Physician Fee Schedule Final Rule which required physicians to sign every lab requisition. However, the AMA, together with numerous other stakeholders including the laboratory industry, strongly opposed this requirement due to significant interruptions in workflow and access to patient care which would result if this requirement were to be retained. CMS initially elected to delay the compliance date for the requirement from January 1, 2011 to April 1, 2011 in order to give physicians, labs and others sufficient time to comply. However, following significant outreach to CMS concerning the impact this requirement would have, CMS has decided to indefinitely postpone the requirement that physicians sign every lab requisition. CMS is expected to propose removing this requirement in future rulemaking.

AMA Correspondence on Lab Requisitions
August 29, 2011 AMA letter to CMS applauding retraction of policy requiring signature on lab requisitions

August 24, 2010 Letter to CMS in response to Proposed Physician Fee Schedule Rule (see page 39)

Additional Resources
March 31, 2011 CMS notification to indefinitely postpone physician signature of lab requisitions

Quality Improvement

The AMA is actively involved in discussing and engaging the Administration and Congress regarding implementation of various quality measurement and improvement programs and activities.

Read More

Recovery Audit Contractors (RAC)

Congress created the recovery audit contractors (RAC) program to help the Centers for Medicare and Medicaid Services (CMS) identify improper payments made by Medicare.  The RAC contractors are private entities that are retained by the government to identify overpayments or under payments made to physicians and other healthcare providers, as well as, to recoup overpayments or return underpayments. The RAC was created by Congress first as a demonstration program and was subsequently expanded as a permanent, nationwide program.

The AMA remains deeply opposed to the bounty hunter-like program.  During the initial stages of the demonstration program, CMS only rewarded the RACs for locating overpayments.  However, thanks to significant AMA advocacy CMS also began rewarding these contractors for locating underpayments as an improper payment could also have resulted in a physician being underpaid.  Several other changes were made to the expanded program as a result of AMA advocacy but the program remains a burden for physicians.

Read More

Red Flags Rule

In 2010, the AMA successfully urged Congress to pass legislation, the "Red Flag Program Clarification Act of 2010," which limits the type of "creditor" that must comply with the Red Flags Rule. In February 2013, the AMA issued comments in response to the FTC's interim final rule that amends the Red Flags regulation to make it consistent with the Clarification Act.

Comments to FTC on Red Flags Interim Final rule amending the Red Flags Regulation, February 8, 2013

AMA letter to the Federal Trade Commission on the Red Flags rule

Self-Referral Law (Stark)
Veterans' Health

The AMA, at its 2014 Annual Meeting, resoundingly adopted new policy that supports the provision of full health benefits to eligible veterans to ensure that they can access the medical care they need outside the Department of Veterans Affairs' (VA) medical centers and other facilities.  This action was in response to recent disturbing reports of unconscionably long wait times and of the unacceptable, unworkable VA appointment scheduling system.

On June 10, the AMA sent a letter to President Obama urging immediate action to provide timely access to entitled care for eligible veterans utilizing the healthcare sector outside the VA until the VA can provide entitled care in a timely fashion.

On March 4, 2015, the AMA sent Interim Final Rule comments to the VA Secretary regarding implementation of the Veterans’ Choice Program, which was authorized under the Veterans Access, Choice, and Accountability Act of 2014

AMA comments to DoD on its proposal to update mental health and substance use disorder benefit coverage, March 31, 2016

Other Issues

AMA/AAFP April 30, 2015 joint letter expressing concern about potential misuse of the Medicare Annual Wellness Visit (AWV) by commercial entities.

AMA signed onto a July 1, 2014 letter expressing concerns regarding CMS final rule changes to the Medicare hospital medical staff Conditions of Participation